The 2A proteinase (2A pro ) of human rhinoviruses cleaves the virally encoded polyprotein between the C terminus of VP1 and its own N terminus. Poor understanding of the 2A pro substrate specificity of this enzyme has hampered progress in developing inhibitors that may serve as antiviral agents. We show here that the 2A pro of human rhinovirus (HRV) 1A and 2 (rhinoviruses from genetic group A) cannot self-process at the HRV14 (a genetic group B rhinovirus) cleavage site. When the amino acids in the cleavage site of HRV2 2A pro (Ile-Ile-Thr-Thr-Ala*Gly-Pro-SerAsp) were singly or doubly replaced with the corresponding HRV14 residues (Asp-Ile-Lys-SerTyr*Gly-Leu-Gly-Pro) at positions from P3 to P29, HRV1A and HRV2 2A pro cleavage took place at WT levels. However, when three or more positions of the HRV1A or 2 2A pro were substituted (e.g.
INTRODUCTION
Human rhinoviruses (HRV), members of the genus Enterovirus within the family Picornaviridae , are the main causative agent of the common cold (Makelä et al., 1998) . Their single-stranded, positive-sense RNA genome contains only one ORF from which a single polyprotein is expressed. Proteolytic processing, performed by the two virally encoded proteases 2A pro and 3C pro , is therefore essential to generate mature viral proteins. In an intramolecular manner, 2A
pro initiates the cascade of cleavages by self-processing the VPI-2A pro junction (Toyoda et al., 1986) . All other proteolytic reactions on the polyprotein are accomplished by 3C
pro (Hanecak et al., 1982; Palmenberg et al., 1979; Skern et al., 2002) .
Enteroviral 2A
pro have been shown to be cysteine proteases with a truncated chymotrypsin-like fold (Baxter et al., 2006; Gorbalenya et al., 1986; Petersen et al., 1999) and a tightly bound zinc ion. They vary in size between 142 and 147 aa for the over 100 known HRV serotypes (Knowles et al., 2012) . HRV2 and HRV14 2A pro (members of rhinoviral group A and group B, respectively) share only about 40 % sequence identity (Skern et al., 1985; Stanway et al., 1984) . Furthermore, their respective VPI-2A pro cleavage sites differ substantially (Fig. 1a) . Thus, HRV2 2A pro cleaves at Ile-IleThr-Thr-Ala*Gly-Pro-Ser-Asp (Sommergruber et al., 1992) whereas HRV14 2A pro processes at Asp-Ile-Lys-Ser-Tyr*GlyLeu-Gly-Pro (Callahan et al., 1985) (the asterisk indicates the scissile bond). Indeed, clear differences in the specificities of these two 2A pro have been documented. Sousa et al. (2006) examined their abilities to self-process at cleavage sites with arginine at P1 (the nomenclature is that of Schechter & Berger, 1967) and found appreciable differences. Crowder & Kirkegaard (2005) pinpointed the potential of 2A pro as a target for antiviral compounds. However, the absence of a high-resolution structure of an HRV 2A pro bound to substrate and the considerable heterogeneity between rhinovirus group A and group B sequences have impeded an exact understanding of substrate binding. Moreover, despite extensive efforts using peptide cleavage assays (Sommergruber et al., 1992; Wang et al., 1997) and fusion proteins (Skern et al., 1991) , the exact specificity of group A and group B 2A
pro self-processing remains cleavage sites. For all reactions, RRLs were programmed with the indicated in vitro-transcribed RNA (10 ng ml "1 ) and incubated at 30 6C. Translated proteins were labelled with [
35 S]methionine. Aliquots (10 ml) were taken at the given time points and the reaction stopped by the addition of 25 ml 2¾ Laemmli sample buffer, 1 ml unlabelled methionine/cysteine (20 mM) and 14 ml H 2 O. Negative controls were prepared by adding water instead of RNA followed by incubation for 300 min. Samples were then analysed by SDS-PAGE (17.5 % acrylamide) (Dasso & Jackson, 1989 ) and proteins were visualized by fluorography. Underlined residues in the cleavage sites indicate variations from the WT HRV2 cleavage site.
unclear, strongly hampering the specific design of compounds that inhibit this reaction.
In order to better understand the mechanism of substrate recognition, we tested whether HRV2 2A pro would be able to self-process at the VPI-2A pro cleavage site found in HRV14. We found that this was not the case either in vitro or in vivo and set out to identify the amino acids that are responsible for this inhibitory effect. Our results show that the occupancy of both P and P9 sites is crucial for efficient processing by HRV2 and HRV1A 2A pro .
RESULTS
HRV2 2A pro cannot cleave intramolecularly at the cleavage site of HRV14 2A pro Fig. 1(a) shows a schematic overview of the in vitro cleavage assay and the residues at the VPI-2A pro junction of the three HRV serotypes examined in this study. The VPI-2A pro cleavage sites of the group A viruses HRV1A and HRV2 exhibited high conservation. In contrast, the cleavage site found in the group B virus HRV14 showed substantial differences from the group A viruses. The differences at positions P1 and P29 attract special attention as both have been reported to be important for substrate recognition (Skern et al., 1991; Sommergruber et al., 1992) .
Self-processing of HRV2 2A pro on its WT cleavage site as observed in rabbit reticulocyte lysate (RRL) is shown in Fig. 1(b) . Unprocessed VPI-2A pro precursor can be detected about 10 min after addition of mRNA to the RRLs. Processed VP1 could also be detected at this time point; the majority of precursor was cleaved after 30 min. Detection of 2A pro was impaired by the low number of methionine residues and the resulting reduced sensitivity. Nevertheless, a faint band could be detected at a molecular mass corresponding to 2A pro at about 30 min.
In order to investigate whether HRV2 2A pro can selfprocess the VPI-2A pro cleavage site found in HRV14, we used site-directed mutagenesis to exchange the residues from P5-P49 of the HRV2 cleavage site with those of the HRV14 site (Fig. 1c) . Differences from the WT HRV2 cleavage site are underlined. Initial translation products could again be detected 10 min after the start of translation. Nevertheless, no processed products could be observed even after 300 min of translation. This indicated that HRV2 2A pro is unable to process this cleavage site.
Next, we aimed to narrow down the residues preventing cleavage by HRV2. Fig. 1 (d, e) shows HRV2 2A pro processing on cleavage sites with corresponding variations in either the P site or the P9 site. Clearly, both of these sites were cleaved, as indicated by the conversion of the VPI-2A pro precursor, even though both mutants showed slightly lowered cleavage kinetics (50 % cleavage of precursor occurred at about 30-60 min).
The results implied that a combination of variations on both sides of the cleavable peptide bond would be necessary to prevent HRV2 2A
pro from processing at the HRV14 site. Accordingly, the variations from P3 to P1 were maintained and combined with single amino acid substitutions at P29, P39 and P49 (Fig. 2) . The most severe effect could be observed when proline at P29 was exchanged for leucine (Fig. 2a) . The VPI-2A pro precursor accumulated over time but no clear pattern of conversion into VP1 and 2A pro was observed during the experiment.
Moving the single amino acid variation at the P9 site further away from the cleavable bond lead to increased activity compared with the P29 leucine mutant (Fig. 2b, c) . Nevertheless, a strong reduction of self-processing activity compared with the WT cleavage site was still observed. In Fig.  2(b, c) , the first cleavage products could be detected 20 min after the start of translation. However, a time point of 50 % turnover of precursor was hard to detect as the pattern showed no clear conversion from precursor to cleavage products but rather an accumulation of cleavage products at a constant level during the course of the experiment. This most probably resulted from a combination of the continuous synthesis of the uncleaved precursor and the presence of a suboptimal cleavage site.
Assuming a more or less extended b-sheet conformation of the substrate in the bound form, the side chain of the P3 residue is most likely to face the solvent. It therefore should not contribute to substrate specificity. For this reason, we decided to mutate lysine at P3 back to the WT threonine leaving just the variations at P2, P1 and P29 (Fig. 3a) . Interestingly, HRV2 2A pro still performed very weakly in processing this site, indicating that these three variations were sufficient to inhibit self-processing to almost 100 %. Nevertheless, we aimed to investigate whether it was possible to reduce the number of substituted residues even further and still observe strong inhibition of self-processing. To this end, we mutated tyrosine at P1 back to the WT alanine and tested the mutant in our in vitro system (Fig. 3b) . The processing kinetics of this mutant were comparable to WT levels (see Fig. 1b ). Hence, tyrosine at P1 was an essential component of the variation that led to inhibition. We could thus define the cleavage site with variations in P2, P1 and P29 as the minimal substitutions required to inhibit the HRV2 2A pro .
Role of the P1 § residue
The above results showed the importance of occupancy at the positions P2, P1 and P29. Although the P19 residue glycine is conserved in all enteroviral 2A pro , it has recently been observed by Park et al. (2010) that two HRV2 2A pro cleavage sites on the nuclear pore protein (Nup) 62 show alanine at P19. In addition, two sites also showed alanine at P29. In order to investigate how the presence of alanine at P19 and P29 influence self-processing, we generated appropriate substitutions for our in vitro system (Figs 3c, d) . The presence of a methyl group at P19 through the introduction of alanine led to a complete inhibition of selfprocessing. In contrast, the substitution of proline with alanine at P29 did not affect cleavage, with processing occurring at essentially WT levels. However, the presence of alanine at P29 in a cleavage site in which the P3-P1 residues had been substituted with those from HRV14 (i.e. P3 Lys, P2 Ser and P1 Tyr) again led to inhibition of HRV2 2A pro self-processing (Fig. 3e) . Indeed, inhibition was comparable to that seen with the mutant bearing leucine at P29 (see Fig. 2a ). This again emphasizes the need for mutations at both sides of the cleavable peptide bond for inhibition.
Specificity of 2A pro in vivo
We then wished to investigate the in vivo phenotype of viruses with variations in the VPI-2A pro cleavage site that inhibited self-processing in vitro and, if possible, isolate second-site revertants that had regained activity. The HRV2 full-length RNA either isolated from virions or transcribed from the cDNA clone described by Duechler et al. (1989) has a low transfection efficiency. Thus, transfection with diethylaminoethyl (DEAE)-dextran of HeLa cells (Ohio strain) with in vitro-transcribed HRV2 RNA yields only about 50 plaques mg 21 (Duechler et al., 1989) . However, the transfection efficiency of the RNA of the closely related genetic A group HRV1A has been reported to be about 2610 5 plaques (mg RNA)
21
( McKnight, 2003) . We could confirm this difference in transfection efficiencies, obtaining 1.5610 5 plaques for HRV1A, 2.5610 3 plaques for HRV 2 and 4.2610 5 plaques for HRV14 (performed as a further control). In order to increase the likelihood of obtaining second-site revertants, we therefore decided to introduce the corresponding mutations into a full-length cDNA clone of HRV1A (McKnight, 2003) . Before starting this approach, we nevertheless first wished to confirm whether the selfprocessing kinetics of HRV2 and HRV1A 2A pro were comparable. Fig. 4 shows that this is indeed the case. Selfprocessing of HRV1A 2A pro on its WT cleavage site reached 50 % after 20-30 min, as did the HRV2 enzyme (compare Fig. 4a with Fig. 1b) . The HRV1A enzyme also failed to cleave when the HRV14 sequence was introduced (Fig. 4b) ; furthermore, the residues determining this property lay at P2, P1 and P29 (Fig. 4c) . Finally, the presence of alanine at P19 led to a complete inhibition of cleavage (Fig. 4d) . Given the very similar self-processing kinetics of HRV2 and HRV1A, we therefore introduced selected mutations into the HRV1A full-length cDNA clone and generated three plasmids subsequently referred to as the HRV1A-HRV14 site (i.e. the sequence shown in Fig. 4b ), HRV1A-P2129SYL (i.e. the sequence shown in Fig. 4c ) and HRV1A-P19A (i.e. the sequence shown in Fig. 4d ). Then, full-length RNA was in vitro transcribed and used to transfect a monolayer of HeLa cells (Ohio strain) with DEAE-dextran, as described in Methods. Upon transfection with WT HRV1A RNA, viral plaques could be detected 48 h post-transfection (p.t.) (Fig. 5a ) at a specific infectivity of 1.5610 5 (mg RNA) 21 ; all cells were lysed at 72 h p.t. (data not shown). In contrast, we were not able to retrieve virus after transfecting HeLa cells with infectious HRV1A-HRV14 site RNA (Fig. 5b) . Even 72 h after transfection, no viral plaques could be observed, indicating that the virus was not viable as a consequence of the multiple changes in this cleavage (Fig. 5c) . A similar situation was observed with mutant HRV1A-P19A [at a specific infectivity of 8.5610 3 (mg RNA)
; Fig. 5d ] 72 h p.t.. In short, these two mutants yielded plaques that were too small to detect at 48 h p.t. and 2-2.5 logs lower in number compared with those observed with WT HRV1A. In addition, heterogeneity in plaque size was observed for both the WT and the mutants. This phenomenon has been recognized for many years for almost all HRV serotypes examined (Acornley et al., 1968; Stott & Killington, 1972) .
To determine whether the viruses obtained after transfection with the mutant HRV1A-P2129SYL and HRV1A-P19A RNAs had maintained the original mutations, had reverted to WT or possessed second-site revertants, small, medium and large viral plaques were picked and freeze/thawed in infection medium to release intracellular virus. The supernatant was used to infect a fresh monolayer of HeLa cells. Plaque purification was repeated for three rounds before cDNA covering the VPI-2A-2B region was amplified by reverse transcriptase (RT)-PCR and sequenced for further analysis. Table 1 shows the results of the sequence analysis using cDNAs amplified from ten plaques of HRV1A-P2129SYL and five plaques of HRV1A-P19A. Generally, we were not able to identify second-site revertants in the sequenced region. However, nine out of ten isolates of HRV1A-P2129SYL were found to have one of two rescue mutations within the cleavage site. No correlation of a particular plaque size with the appearance of a particular mutation was observed. In six cases, we identified a Tyr-to-Cys mutation at P1 whilst in three other sequences we observed a Leu-to-Pro mutation at P29. Proline at P29 is the WT residue found in the HRV1A VPI-2A pro junction. In contrast, cysteine at the P1 site is not a naturally occurring amino acid in any of the introduced HRV serotypes. Given the three possible residues created by a single base transition from the tyrosine codon (cysteine, histidine, tyrosine), cysteine exhibits the smallest space requirements and might therefore best mimic the WT alanine. We also observed one viral plaque with the original transfected cleavage site, indicating that self-processing at this site was not completely inhibited. This plaque did not show a small-plaque phenotype. Sequence analysis of the VPI-2A-2B region of the virus from this plaque confirmed the presence of the WT sequence.
In contrast, analysis of all five isolates of HRV1A-P19-A showed that the alanine codon at P19 had reverted back to the codon for the WT residue glycine, with the same double base mutation being detected in all five cDNAs examined.
DISCUSSION
The absence of the structure of an enteroviral 2A pro complexed to a substrate or inhibitor has hampered a clear understanding of the determinants of the substrate specificity of these enzymes. The experimental basis of the work shown here illustrates this problem as we cannot at present explain why the HRV1A or HRV2 2A pro cannot carry out self-processing on the HRV14 cleavage sequence, even though the introduction of the respective amino acids one at a time does not affect cleavage. Our in vitro mutational approach coupled with the in vivo selection of revertant viruses demonstrated that at least three residues must be modified in the HRV2 or HRV1A cleavage site to inhibit cleavage; however, this inhibition can be relieved by the modification of just one of the three amino acids. Thus, spatial requirements may dominate over absolute sequence constraints in determining substrate specificity.
In addition, we also showed that glycine at P19 in the cis self-processing reaction cannot be replaced by Ala. This is in contrast to the trans cleavage reaction for which two sites have been determined that show alanine at P19; both are in the cellular substrate Nup62 (Park et al., 2010) . What is the reason for the requirement of glycine at P19 in the cis reaction? Petersen et al. (1999) proposed that Leu19 is the key residue that, through its bulk, prevents the acceptance of residues other than glycine at P19 by blocking space required for a side chain (Petersen et al., 1999) . We therefore mutated Leu19 to alanine in HRV2 2A pro and examined self-processing with the P19 Gly-to-Ala mutant. This mutant should possess sufficient space for the alanine side chain at P19; nevertheless, almost no processing could be observed (data not shown), suggesting that Leu19 is not involved in determining P19 specificity. Our attempts to find residues involved in P19 discrimination by searching for second site revertants using an HRV1A 2A pro P19 Glyto-Ala mutant were unsuccessful (Table 1) , possibly indicating that more than one residue is involved.
To structurally analyse spatial requirements of 2A pro substrate binding as well as P19 discrimination in the absence of the structure of a complex of 2A pro and a substrate or inhibitor, we built a model of the binding of the HRV2 2A pro to the heptapeptide Ile-Ile-Thr-Thr-AlaGly-Pro (IITTAGP) spanning the region from P5 to P29 of the cleavage site. To this end, we used the DaliLite server (Holm & Sander, 1993a) to align HRV2 2A pro with Streptomyces griseus protease B (SGPB) complexed to the amino acid sequence Pro-Ala-Cys-Thr-Leu-Glu-Tyr (PACTLEY), which corresponds to residues P5 to P29 of the third domain of the turkey ovomucoid inhibitor (OMTKY3). Subsequently, the amino acid side chains of the OMTKY3 residues were mutated to the P5 to P29 sequence IITTAGP of the HRV2 2A pro cleavage site using Pymol (Fig. 6a) . Overall, the mutated peptide fitted well into the substrate-binding site of the HRV2 2A pro . However, a major difference between the two enzymes was the presence of the loop between strands bII2 and cII in HRV2 HRV1A-WT 48 h p.t.
HRV1A-P1′A
72 h p.t.
HRV1A-HRV14 site 72 h p.t.
HRV1A-P212′SYL 72 h p.t.
Neg. 72 h p.t. Human rhinovirus 2A pro specificity 2A pro covering the Asp35 residue (Fig. 6a, enlargement) . The tyrosine (Tyr85) residue at the end of the loop collides with the side chain of the P2 threonine residue. This has been noted previously by Petersen et al. (1999) who used a different structural alignment approach to position the main chain of the OMTKY3 peptide in the binding site. To examine the arrangement of the HRV14 2A pro cleavage sequence in HRV2 2A pro , we then extended the model by mutating the peptide IITTAGP to Ile-Ile-Thr-Ser-Tyr-GlyLeu (IITSYGL) (Fig. 6b) . Again, Tyr85 still clashed with the P2 serine residue. In addition, at P1, the side chain of the tyrosine residue now lies very close to b-strand eII. In contrast, the leucine residue at P29 does not appear to be causing any steric clashes.
We then minimized this model using the YASARA energy minimization server (Krieger et al., 2009) as shown in Fig.  6(c) . Root-mean-square deviation analysis, measured with the Pymol command 'rms_cur', of positions of the C a atoms of the non-minimized and minimized peptides showed a difference of 0.73 Å , indicating that the backbone of the substrate moved further into the binding cleft. In addition, the tyrosine at P1 showed rotation about the C a -C b and C b -C c bonds placing the side chain in the middle of the P1 pocket. Of the residues in the enzyme, there was clear movement of the residue Tyr85 in the loop-covering residue Asp35. Thus, the side chain of Tyr85 had been rotated 101 u about its C a -C b bond. Substrate-induced movement of this residue was indeed predicted by Petersen et al. (1999) .
Close examination of the minimized structure revealed that two residues came close to the glycine in the P19 position of the substrate. These were the catalytic His18 and Tyr85 (distances 3.6 and 3.7 Å from P19 Gly C a to His18 N e and to Tyr85 C e , respectively). Both residues are fully conserved in all enteroviral 2A pro proteins. The presence of any other residue at P19 would thus cause a steric clash with His18 and Tyr85 side chains and explain the absolute requirement for glycine at P19 in self-processing. In addition, this would imply that the movement of the side chain of Tyr85 is required for specificity, providing an explanation for the absolute conservation of this residue in all enteroviral 2A pro proteins. How can alanine be accepted for in trans cleavage at the P19 position? One possibility might be that, in the cis reaction, the N-terminal residues of 2A pro enter the substrate-binding site before those of the C terminus of VP1. The presence of alanine at P19 may therefore prevent the movement of Tyr85 and the binding of the VP1 sequence. In contrast, in the trans reaction, the substrate is not covalently linked to the enzyme, so that the constraints on substrate binding may be more relaxed, giving Tyr85 greater freedom of movement.
The minimization of this model supports our experimental observations that single substitutions of the amino acids of the HRV14 cleavage site at P2, P1 and P29 can all be accepted by the HRV2 2A pro . The model does not however explain why the presence of all three lead to inhibition of HRV2 or HRV1A 2A
pro self-processing. We propose that the reason may lie in the smaller Ser residue at P2 that is less effective than Thr in driving Tyr85 out of the substrate-binding pocket. In addition, the presence of the Tyr P1 and Leu P29 side chains may destabilize substrate binding through their bulky side chains. In this way, substrate specificity would appear to depend on more spatial properties than on recognition of the sequence itself. Such a phenomenon has also been observed for the HIV-1 proteinase that recognizes the asymmetrical shape of a group of amino acids rather than their primary sequence (Nalam et al., 2010) .
Are there differences in the residues of HRV2 and HRV14 2A
pro that surround the substrate-binding site or in the area of Tyr85? To investigate this point, we compared the amino acid sequences of the two enzymes and mapped the differences on the HRV2 2A pro structure (Fig. 7) . Even though there is only a 40 % conservation of the amino acid sequence, there is a high level of conservation of the residues flanking the P1 pocket (eII and cII and dII). Indeed, only one residue differs in this region, namely at position 101 with cysteine present in HRV2 and alanine in HRV14. This residue has been previously shown to be involved in preventing HRV14 from accepting arginine at P1 (Sousa et al., 2006) . pro model bound to a peptide corresponding to the HRV14 2A pro cleavage site before (b) and after (c) energy minimization using the YASARA energy minimization server (Krieger et al., 2009) . The colour code is as in (a), except that carbon atoms are coloured brown. b-Strands of the C-terminal domain of HRV2 2A pro are labelled according to SGPB nomenclature (Delbaere et al., 1979; Petersen et al., 1999) . The side chains of the indicated active site residues as well as Tyr85 are shown. Drawings were done with Pymol (DeLano, 2002) .
Human rhinovirus 2A pro specificity
Another difference lies in the residues in the loop connecting eII with fII. However, all the side chains in this loop point outwards, away from the S1 binding pocket. However, none of the other differences noted could be interpreted as influencing substrate specificity. This again supports the notion that spatial rather than sequence requirements are involved in determining substrate specificity.
In addition to the difference in sequences at the VPI-2A junction between genetic A and B group rhinoviruses, genetic B group viruses also possess two more amino acids between the N terminus and the first predicted b-strand. It seems possible that this may make the N-terminal extension more flexible, thus influencing cleavage efficiency. We are currently investigating the role of these two extra, highly conserved amino acids in vitro and in vivo using deletion analysis.
In summary, we have presented experiments showing that substrate recognition by HRV 2A pro is not a simple matter of the recognition of certain amino acid side chains but is rather restricted by as yet undetermined spatial considerations. Although the results are based on an energyminimized model, they suggest that the reason for the conservation of Tyr85 is its movement on substrate binding that then restricts the residues that can be accepted at P19 to glycine. Further experiments will be performed to test this hypothesis.
METHODS
Construction of plasmids. pHRV2 VPI-2A pro encoding HRV2 VP1 and 2A
pro cloned downstream to the encephalomyocarditis virus internal ribosome-entry site (CITE) and a T7 promoter has been described (Glaser et al., 2003) . pHRV1A VPI-2A pro encodes the HRV1A VP1 and 2A pro and was generated from pHRV2 VPI-2A pro by replacing the VPI-2A pro coding sequence via NcoI/BamHI sites. Substitutions at the VPI-2A pro cleavage site were introduced via synthetic oligonucleotide cassettes. Restriction enzyme sites (BsiWI and BstEII) were introduced around the cleavage site without changing the amino acid sequences to facilitate the introduction of the cassettes. For transfection experiments, mutated cleavage sites were introduced into a full-length cDNA clone of HRV1A via cassette cloning. Again restriction enzyme sites BsiWI/BstEII were introduced and used for cloning.
In vitro transcription and translation. Following linearization with BamHI (pHRV2 VPI-2A pro and pHRV1A VPI-2A pro ) or with MluI (HRV1A full-length clone), DNA was purified via the Wizard SV Gel and PCR Clean-Up System (Promega) and transcribed in vitro with T7 RNA polymerase for 2 h at 37 uC. Reactions (100 ml) contained 10-15 mg linearized DNA, 100 mM sodium phosphate (pH 7.7), 50 mM DTT, 0.5 mM NTPs, 20 mM spermidine (HCl) 3 , 40 mM 
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